Terms: = Kidney tumors AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M AND Treatment
4 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Occurrence of non-central nervous system cancers during postoperative follow-up of patients who underwent surgery for a WHO grade II glioma: implications for therapeutic management.
Duffau H
J Neurooncol; 2023 Mar; 162(1):237-244. PubMed ID: 36913047
[TBL] [Abstract] [Full Text] [Related]
3. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.
Toledo RA; Jimenez C; Armaiz-Pena G; Arenillas C; Capdevila J; Dahia PLM
Endocr Rev; 2023 Mar; 44(2):312-322. PubMed ID: 36301191
[TBL] [Abstract] [Full Text] [Related]
4. Dysregulation of the Sirt5/idh2 axis contributes to sunitinib resistance in human renal cancer cells.
Meng L; Chen D; Meng G; Lu L; Han C
FEBS Open Bio; 2021 Mar; 11(3):921-931. PubMed ID: 33455080
[TBL] [Abstract] [Full Text] [Related]
